Showing 1391-1400 of 1477 results for "".
- FDA Panel Endorses Pfizer, BioNTech’s COVID-19 Vaccinehttps://modernod.com/news/fda-panel-endorses-pfizer-biontechs-covid-19-vaccine/2478650/An FDA advisory panel that convened Thursday to discuss Pfizer and BioNTech’s COVID-19 vaccine BNT162b2 voted 17-4, with one abstention, in favor of authorizing it for emergency use in people 16 years and older. The vote follows the release of briefing documents earlier this week in which F
- Vitamin Sciences Lauches Visivite Blue Light Basher Ocular Supplementhttps://modernod.com/news/vitamin-sciences-lauches-visivite-blue-light-basher-ocular-supplement/2478604/Vitamin Science has added to its arsenal of quality ocular supplements with its launch of VisiVite Blue Light Basher earlier this year. High energy blue light is everywhere—cell phones, TV’s, LED lights and sunlight itself. To
- NovaBay Pharmaceuticals Expands Avenova’s Geographic Reach to Australia with New Exclusive Distribution Agreementhttps://modernod.com/news/novabay-pharmaceuticals-expands-avenovas-geographic-reach-to-australia-with-new-exclusive-distribution-agreement/2478586/NovaBay Pharmaceuticals announced the signing of an agreement with Paragon Care Group Australia Pty for the exclusive distribution of Avenova in Australia. Paragon Care Group will begin distributing Avenova directly to consumers under its Designs For Vision brand beginning in early 2021. “
- Zeiss Introduces Video Laryngoscopehttps://modernod.com/news/zeiss-introduces-video-laryngoscope/2478531/With the outbreak of the COVID-19 crisis earlier this year, the Medical Technology segment of Zeiss focused on he
- AstraZeneca, J&J Say Their COVID-19 Vaccine Trials Back on Track in UShttps://modernod.com/news/astrazeneca-jj-say-their-covid-19-vaccine-trials-back-on-track-in-us/2478455/AstraZeneca announced Friday that it has been cleared to restart its phase 3 COVID-19 vaccine trial in the US. The company, which is co-developing AZD1222 with the University of Oxford, had paused global testing of the vaccine candidate early last month after a UK participant fell ill with what i
- Suspected Control Group Participant in AstraZeneca COVID-19 Vaccine Study Dies; Trial Continueshttps://modernod.com/news/suspected-control-group-participant-in-astrazeneca-covid-19-vaccine-study-dies-trial-continues/2478449/Brazilian health authority Anvisa said that a participant in a clinical trial there of AstraZeneca’s experimental COVID-19 vaccine AZD1222 died earlier this week, but added that the study would nevertheless go on. AstraZeneca stated it cannot comment on individual cases because of confident
- Sources Say US Study of AstraZeneca’s COVID-19 Vaccine May Restart This Weekhttps://modernod.com/news/sources-say-us-study-of-astrazenecas-covid-19-vaccine-may-restart-this-week/2478439/According to a report Tuesday citing four sources, the US trial of AstraZeneca’s COVID-19 vaccine AZD1222 is expected to resume as early as this week after the FDA completed its review of a serious adverse event that had prompted a hold on global testing of the candidate last month. The pha
- Volunteers to be Infected With Coronavirus in World’s First ‘Human Challenge’ Trialshttps://modernod.com/news/volunteers-to-be-infected-with-coronavirus-in-worlds-first-human-challenge-trials/2478437/Volunteers in London are to be infected with coronavirus early next year, in the world’s first COVID-19 “human challenge trials,” according to a Financial Times report. The project, first disclosed in the Financial Time
- Oxular Receives Rare Paediatric Disease and Orphan-Drug Designations for Retinoblastoma Treatmenthttps://modernod.com/news/oxular-receives-rare-paediatric-disease-and-orphan-drug-designations-for-retinoblastoma-treatment/2478404/Oxular Limited announces it has received both rare paediatric disease and orphan drug designations from the FDA for OXU-003, the company’s proprietary drug in development for the treatment of retinoblastoma. Retinoblastoma is a rare form of eye cancer that usually develops in early childho
- GSK, Vir Biotechnology Move Anti-SARS-CoV-2 Monoclonal Antibody Into Phase 3https://modernod.com/news/gsk-vir-biotechnology-move-anti-sars-cov-2-monoclonal-antibody-into-phase-3/2478385/GlaxoSmithKline and partner Vir Biotechnology announced that the COMET-ICE study evaluating VIR-7831 as an early treatment for COVID-19 patients deemed to be at high risk of hospitalization will proceed into phase 3 testing, with preliminary results coming possibly before the end of this year. Th